NCT04747678

Brief Summary

retrograde study of common and rare adverse effects of multiple doses of ivermectin used during the coivd 19 pandemic in egypt

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 1, 2021

Completed
2 days until next milestone

Study Start

First participant enrolled

February 3, 2021

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 10, 2021

Completed
18 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2021

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2021

Completed
Last Updated

February 10, 2021

Status Verified

February 1, 2021

Enrollment Period

25 days

First QC Date

February 1, 2021

Last Update Submit

February 9, 2021

Conditions

Covid19Ivermectin PoisoningDrug ToxicityDrug Side Effect

Outcome Measures

Primary Outcomes (1)

  • all adverse effects will be collected from people used Ivermectin in between September 2020 to December 2020

    all data will be collected from retrospective manner as a retrospective study

    the data will be collected from February 2021 to march 2021

Secondary Outcomes (1)

  • all data will be arranged according to time and dose manner

    February to match 2021

Interventions

IvermectinDRUG

retrograde study of common and rare adverse effects of multiple doses of ivermectin used during the coivd 19 pandemic in egypt

Eligibility Criteria

Age16 Years - 80 Years
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

all healthy and diseased people who used ivermectin the last three months either as a treatment or as a prophylaxis with mention of the doses used and the adverse effects experienced during and after the usage

You may qualify if:

  • all people used ivermectin as a treatment or as a prophylactic in covid 19 pandemic in egypt with explained dose

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ahmed Mansour

Shibīn al Kawm, Menoufia, 24222, Egypt

Location

MeSH Terms

Conditions

COVID-19Drug-Related Side Effects and Adverse Reactions

Interventions

Ivermectin

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesChemically-Induced Disorders

Intervention Hierarchy (Ancestors)

MacrolidesPolyketidesLactonesOrganic Chemicals

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
CROSS SECTIONAL
Target Duration
30 Days
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 1, 2021

First Posted

February 10, 2021

Study Start

February 3, 2021

Primary Completion

February 28, 2021

Study Completion

March 1, 2021

Last Updated

February 10, 2021

Record last verified: 2021-02

Locations

EG(1)